Boston Scientific Traded 90th in Volume as FDA Delays Weigh on Recovery Despite Asia-Pacific Distribution Pact and 0.39% Rally

On October 2, 2025, Boston Scientific (BSX) traded with a volume of $1.15 billion, marking a 46.06% decline from the previous day’s activity and ranking 90th in market volume. The stock closed with a 0.39% gain, reflecting a modest recovery amid broader market volatility.

Recent developments suggest a mixed outlook for the medical device manufacturer. A regulatory update from the FDA highlighted ongoing delays in the approval of next-generation stent technology, raising concerns about competitive positioning. Meanwhile, a partnership with a European distributor to expand catheter product distribution in the Asia-Pacific region added short-term optimism. Analysts noted that while the FDA news could pressure R&D timelines, the distribution deal may bolster near-term revenue streams.

Market participants observed muted trading activity as investors balanced near-term operational updates against macroeconomic uncertainties. The stock’s volume contraction suggests reduced speculative interest compared to recent weeks, though earnings expectations for Q4 remain stable. Institutional buyers have maintained a neutral stance, with no significant share buyback programs announced.

To run this back-test for you I need to pin down a few practical details: 1. Universe – Which market should we draw the “top-500-by-volume” list from each day? 2. Entry & exit prices – Buy at the same day’s close and exit at the next day’s close (close-to-close), or another convention? 3. Portfolio construction – Equal-weight across the 500 names each day, or another weighting method? 4. Benchmark – Would you like the results compared with a benchmark index such as SPY? Once these points are clarified I can generate the daily trade lists and run the back-test.